Background: Graves' disease (GD), a prototypical autoimmune disorder, is associated with other autoimmune diseases, including vasculitis. Antithyroid drugs, despite their postulated immunosuppressive effects, may cause several autoimmune disorders. Here we describe the first patient with central nervous system (CNS) vasculitis that developed shortly after the start of methimazole (MMI) treatment for GD. Patient Findings: CNS vasculitis was suspected on the basis of the clinical features and neurologic examination, showing a reinforcement of deep reflexes, especially of the left knee and Achilles reflexes. The diagnosis was confirmed by a brain magnetic resonance imaging (MRI), which showed some hyperintensive spots in the subcortical substantia alba and in the parietal area bilaterally, and by a single-photon emission computed tomography (SPECT) imaging, which showed a nonhomogenous distribution of the blood flow in the brain, with a reduced perfusion on the left side of the frontotemporal and parietal regions, and on the right side of the frontotemporal area. MMI was stopped before total thyroidectomy, and symptoms resolved in the next 5 weeks. Six months after MMI was stopped, the brain MRI and SPECT had become normal. Summary: To our knowledge, this is the first report of CNS vasculitis related to MMI therapy.
Introduction
G raves' disease (GD) is the most common cause of thyrotoxicosis in young women living in iodinesufficient areas. It is induced by autoantibodies directed against the thyroid-stimulating hormone (TSH) receptor (TRAb). Medical treatment of GD is based chiefly on the thionamide antithyroid drugs (1) . These exert their antithyroid effect by inhibiting thyroid hormone synthesis (1) . They have also been postulated to have an immunosuppressive action that promotes remission of GD (1, 2) . Methimazole (MMI) and propylthiouracil (PTU) are the most frequently used thionamide drugs for GD. Adverse effects, including skin rash, liver dysfunction, and agranulocytosis, have been associated with both drugs.
There have been multiple patients reported with PTUassociated vasculitis in the past 2 decades, mostly in females, consistent with the fact that GD is more common in this sex than in males (3) (4) (5) (6) . Almost all patients with PTU-induced vasculitis have detectable antineutrophil cytoplasmic antibody (ANCA) levels, although not all PTU-ANCA-positive patients develop a clinical disease (4) (5) (6) (7) (8) (9) (10) (11) . The clinical presentation and severity have been variable (3-10) with rare fatalities (11) . Dermatological manifestations (usually urticaria or macular rashes) and arthralgias are the most common features of PTU-associated vasculitis. There is lesser frequency of renal or pulmonary involvement, which is more serious (3) (4) (5) (6) (7) (8) (9) (10) . Vasculitis associated with MMI therapy has also been described, but is less common than with PTU.
Interestingly, a patient with central nervous system (CNS) vasculitis caused by PTU therapy has recently been described (12) . Here we report the first patient with CNS vasculitis that appears to be related to MMI treatment. The disorder began soon after MMI was started and resolved shortly after it was stopped.
Patient
A 22-year-old woman was seen in our outpatient clinic in December 2002 because of fatigue, palpitations, tremor, insomnia, sweating, and weight loss of 1-month duration. Past medical history was significant for glomerulonephritis at 12 years of age. Physical examination revealed warm, moist skin; tremors of the extremities; hyper-reflexia; and a diffuse goiter. Her heart rate was 100 beats=min, and her mean blood pressure was 150=70 mmHg. Despite complaints of photophobia, only stare and eyelid retraction were present on neuroophthalmological exam. Funduscopic examination was normal. Visual field examination was not performed. The serum TSH was 0.010 mU=L (normal range, 0.270-4.2 mU=L), and the serum free triiodothyronine (FT3) and free thyroxine (FT4) levels were elevated (FT3, 26.3 pmol=L; normal range, 3.0-6.7 pmol=L; FT4, 70.4 pmol=L; normal range, 12.0-22.0 pmol=L). Serum TRAb was markedly increased (80 IU=L; normal value, <1.5 IU=L), whereas antithyroglobulin antibodies and antiperoxidase antibodies were absent. Ultrasound examination showed a diffuse enlargement of the thyroid gland, associated with hypoechogenicity and a diffusely increased thyroid blood flow. All findings were consistent with GD, and the treatment with MMI 30 mg=day was started, with progressive attenuation of symptoms and signs of thyrotoxicosis and normalization of FT3 and FT4 values.
Three weeks later, she was seen at our outpatient clinic because of the acute onset of severe headache and left-sided paresthesia. Neurologic examination showed hyperactive deep tendon reflexes, especially of the left knee and Achilles reflexes. Visual-evoked potentials revealed the presence of a P100 wave with little amplitude and altered morphology, bilaterally, whereas auditory-, somatosensory-, and motorevoked potentials were normal. Baseline chemistry, blood count, white blood cell differential, hepatic and renal function, and total blood homocysteine values were all within the normal laboratory range. Coagulation studies showed increased levels of fibrinogen (509 mg=dL; normal range, 180-350 mg=dL), activated partial thromboplastin time (46.9 seconds; normal range, 21-35 seconds), and C-reactive protein (113 mg=dL; normal range, 0.00-0.50 mg=dL). Lupus-like anticoagulant LAC (74.3 seconds; normal range, 0-42 seconds) and immunoglobulins IgM (288 mg=dL; normal range, 40-230 mg=dL) were increased, whereas IgG was within the normal range. Antinuclear antibodies, pANCA and cANCA, antinative DNA antibodies, and extractable nuclear antigen were negative. Noncontrast brain magnetic resonance imaging (MRI) showed some hyperintensive spots (1-8 mm in diameter) located in the subcortical substantia alba and in the parietal area bilaterally. This imaging was compatible with the clinical impression of probable CNS vasculitis. Single-photon emission computed tomography (SPECT) imaging of regional cerebral blood flow performed with 99m Technetium-ethyl cysteinate dimer confirmed the diagnosis of CNS vasculitis, showing a nonhomogenous distribution of the blood flow in the brain, with a reduced perfusion on the left side of the frontotemporal and parietal regions, and on the right side of the frontotemporal area (Fig. 1A) . The patient was started on immunosuppressive therapy with azothioprine 50 mg daily, and adjuvant therapy with ranitidine 100 mg daily, carbamazepine 200 mg daily, aspirin 100 mg daily, and furosemide 25 mg daily. Within 4 weeks of starting these drugs for CNS vasculitis, the clinical status of the patient improved, neurological symptoms and signs partially recovered, and coagulation tests and Lupus-like anticoagulant LAC normalized.
Two months after coming to the hospital with neurological symptoms, she underwent near-total thyroidectomy, and MMI therapy was discontinued. Complete resolution of the cerebral vasculitis occurred 5 weeks after surgery and discontinuation of MMI. Six months after her hospitalization for CNS vasculitis, MRI was normal (not shown), and SPECT (Fig. 1B) showed complete recovery of the CNS vasculitis. At the last follow-up, 4 years after having vasculitis, there has been no relapse.
Discussion
Here we describe a young woman with GD who developed CNS vasculitis 3 weeks after starting on MMI. The close proximity of CNS vasculitis to the start of MMI and that CNS vasculitis resolved within 5 weeks of stopping MMI are very consistent with this drug being the cause of her CNS vasculitis and has not been previously reported. Vasculitis is one of the major toxic reactions to antithyroid drugs (13) . It is usually associated with PTU therapy (4-11,13), but MMIrelated vasculitis has been reported (14) (15) (16) . Because vasculitis is more often associated with PTU than with MMI, the latter antithyroid drug has been advocated as safer for the management of GD (5, 11, 13) .
Patients with drug-induced vasculitis usually have a good prognosis and a milder course than those with idiopathic vasculitis, in part because the underlying cause can be removed by stopping the drug. In a series of 16 patients (12 receiving PTU and 4 receiving MMI), none manifested CNS effects, but one did have sensory polyneuropathy that regressed upon the drug was stopped (10) . The first patient with CNS vasculitis in association with antithyroid drug treatment was reported in 2005 (12) . This patient was taking PTU. We are not aware of any reports before this of CNS vasculitis related to MMI therapy. Most of the reported patients with antithyroid drug-induced vasculitis are ANCA positive, although not all ANCA-positive patients develop the disease. In our patient, ANCA (as well as other nonorgan-specific autoantibodies) was always negative, consistent with the notion that ANCA is not critical for developing drug-induced vasculitis.
GD and Hashimoto's thyroiditis are both autoimmune disorders. Vasculitis in patients with these two disorders is exceedingly rare and may be based on chance or the presence of other autoimmune disorders when reported (17) (18) (19) . In the patient reported here, the development of CNS vasculitis was clearly associated with MMI treatment, not the presence of GD. This patient illustrates that the risk of vasculitis cannot be entirely avoided by prescribing MMI instead of PTU.
